COMMUNIQUÉS West-GlobeNewswire

Altimmune to Participate at Two Investor Conferences in March

06/03/2018 - 14:00

GAITHERSBURG, Md., March 06, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT ), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a [...]

CymaBay to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 15

06/03/2018 - 14:00

NEWARK, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY ), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high [...]

Allena Pharmaceuticals Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric Hyperoxaluria

06/03/2018 - 14:00

URIROX-1 TM is the Largest Controlled Trial of a Novel Therapeutic for this Underserved Patient Population - Topline Data Expected in Second Half of 2019 - ALLN-177 has Potential to be the First FDA-Approved Treatment [...]

PhaseBio to Present at March Investor Conferences

06/03/2018 - 14:00

MALVERN, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, today announced that Chief Executive [...]

Albireo to Present at 38th Annual Cowen and Company Health Care Conference

06/03/2018 - 14:00

BOSTON, March 06, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO ), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President [...]

CareDx to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on March 22, 2018

06/03/2018 - 14:00

BRISBANE, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA ), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value [...]

MyoKardia to Present at the Cowen and Company 38th Annual Health Care Conference

06/03/2018 - 14:00

SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK ), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable [...]

GBT Appoints Industry Leader David L. Johnson as Chief Commercial Officer

06/03/2018 - 14:00

SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the “Company”) (Nasdaq: GBT ) today announced the appointment of David L. Johnson as chief commercial officer, [...]

3D Signatures Inc. and l’Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) Announce Collaboration to Combine TeloView™ with Genome Sequence Analysis in Lung Cancer

06/03/2018 - 14:00

TORONTO, March 06, 2018 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V: DXD ) (OTCQB:TDSGF) (FSE:3D0) (the " Company " or " 3DS "), a personalized medicine company with a proprietary software platform based on the three- [...]

Phase 1 Clinical Data Demonstrating CLR 124 Uptake in Brain Tumors Accepted for Oral Presentation at the 12th World Congress of the World Federation of Nuclear Medicine and Biology

06/03/2018 - 14:00

MADISON, Wis., March 06, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB ), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment [...]

Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma

06/03/2018 - 14:00

EXTON, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC ), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today [...]

HempAmericana Announces Purchase of Next Generation CBD Purification System

06/03/2018 - 14:00

NEW YORK, March 06, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- HempAmericana, Inc. (OTC:HMPQ) (“HempAmericana” or the “Company”) is proud to announce the Company’s purchase of a Gilson CPC 1000 centrifugal partition [...]

Emerald Health Therapeutics Grants Options to Executive

06/03/2018 - 13:49

VICTORIA, British Columbia, March 06, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) (Emerald) issued 120,000 incentive stock options to Paul Dillman, VP Marketing and Sales. The [...]

KemPharm to Present at Upcoming Investor Conferences

06/03/2018 - 13:30

Presentations to Highlight Corporate and Clinical Progress CORALVILLE, Iowa, March 06, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH ), a specialty pharmaceutical company focused on the discovery and development [...]

Flexion Therapeutics Presents Clinical Data at AAOS 2018 Annual Meeting and the American Pain Society Annual Scientific Meeting

06/03/2018 - 13:30

Post-hoc analysis demonstrates potential of ZILRETTA ® (triamcinolone acetonide extended-release injectable suspension) to provide effective pain relief regardless of prior intra-articular corticosteroid use Effects of [...]

Evoke Pharma to Present at the Upcoming Roth and Oppenheimer Investor Conferences

06/03/2018 - 13:30

SOLANA BEACH, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK ), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave [...]

Kura Oncology to Present at Cowen and Company 38th Annual Health Care Conference

06/03/2018 - 13:30

SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA ), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its [...]

Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results

06/03/2018 - 13:30

RADNOR, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS ), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric [...]

Protalix BioTherapeutics Reports 2017 Full Year Results and Provides Corporate Update

06/03/2018 - 13:30

Enrollment in all Fabry Trials is ongoing in over Forty Active Sites Current Cash is Projected to Fund the Company through Clinical Trial Read-Outs and into 2020 CARMIEL, Israel, March 06, 2018 (GLOBE NEWSWIRE) -- [...]